. 2025 Jan 3;74(2):58. doi: 10.1007/s00262-024-03882-4

Table 1.

Response rate and patients’ progression in univariate analysis

Parameters		Response rate (%)	Odds ratio (OR); 95% CI; p value	Progression rate (%)	Odds ratio (OR); 95% CI; p value
(A) Immunotherapy (ICIs alone and ICIs + chemotherapy)
HGF Baseline (pg/mL)	Low (12)	75	2.7 (0.62–11.58); p = 0.09	8	0.14 (0.02–1.23); p = 0.02
HGF Baseline (pg/mL)	High (36)	53	2.7 (0.62–11.58); p = 0.09	39	0.14 (0.02–1.23); p = 0.02
HGF First Evaluation (pg/mL)	Low (9)	78	0.62 (0.18–2.16); p = 0.23	11	0.30 (0.03–2.78); p = 0.133
HGF First Evaluation (pg/mL)	High (27)	56	0.62 (0.18–2.16); p = 0.23	30	0.30 (0.03–2.78); p = 0.133
(B) ICIs alone
HGF Baseline (pg/mL)	Low (6)	85	9.00 (0.9–89.66); p = 0,02	0	0.07 (0.003–1.32); p = 0,0092
HGF Baseline (pg/mL)	High (21)	33	9.00 (0.9–89.66); p = 0,02	50	0.07 (0.003–1.32); p = 0,0092
HGF First Evaluation (pg/mL)	Low (6)	83	55.00 (2.83–1069); p < 0.001	0	0.5 (0.04–6.02); p = 0.29
HGF First Evaluation (pg/mL)	High (12)	43	55.00 (2.83–1069); p < 0.001	48	0.5 (0.04–6.02); p = 0.29
(C) COMBO (ICIs + chemotherapy)
HGF Baseline (pg/mL)	Low (5)	60	2.55 (0.23–27.72); p = 0.22	20	0.75 (0.06–8.84); p = 0.41
HGF Baseline (pg/mL)	High (16)	69	2.55 (0.23–27.72); p = 0.22	25	0.75 (0.06–8.84); p = 0.41
HGF First Evaluation (pg/mL)	Low (5)	80	0.23 (0.21–26.84); p = 0.23	20	0.75 (0.06–5.61); p = 0.41
HGF First Evaluation (pg/mL)	High (16)	63	0.23 (0.21–26.84); p = 0.23	0	0.75 (0.06–5.61); p = 0.41
(D) Chemotherapy (CT)
HGF Baseline (pg/mL)	Low (10)	40	1.17 (0.25–5.42); p = 0.42	30	1.46 (0.27–7.82); p = 0.33
HGF Baseline (pg/mL)	High (22)	36	1.17 (0.25–5.42); p = 0.42	23	1.46 (0.27–7.82); p = 0.33
HGF First Evaluation (pg/mL)	Low (7)	43	0.84 (0.14–4.98); p = 0.43	14	0.16 (0.04–5.00); p = 0.26
HGF First Evaluation (pg/mL)	High (17)	47	0.84 (0.14–4.98); p = 0.43	24	0.16 (0.04–5.00); p = 0.26